REGISTERED COMPANY NUMBER: 07955451 {England and Wal$s) REGISTERED CHARrrY NUMBER: 1147457 Report of the Trustees and Financial Statements for the Year Ended 31 Decernber 2020 THE HPV AND ANAL CANCER FOUNDATION LIM￿ED Knox Cropper LLP Charte￿d Accountants 65 Lèadenhall Street London EC3A 2AD THE HPV AND ANAL CANCER FOUNDATION LIMITED Contents of the Financial Ststements for the Year Ended 31 December 2020 Page Reference and Administrative Details Report of the Trustees 2 to 14 Independent Examiner's Report 15 Statement of Financial Activities 16 Balance Sheet 17 Notes to the Financial Statements 18 to 26 Detailed Statement of Financial Activities 27 to 28 THE HPV AND ANAL CANCER FOUNDATION LIMITED Reference and Administrative Details for the Year Ended 31 December 2020 TRUSTEES C Ajmada J Amada T Almada C Levett REGISTERED OFFICE Kemp House 160 CtyRoa London London EC1V 2NX REGISTERED COMPANY NUMBER 07955451 (England and Wales) REGISTERED CHARrrY NUMBER 1147457 INDEPENDENT EXAMINER Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD SOLICITORS Stone King 16 Sl. John's Lane London EC1M 4BS BANKERS HSBC 455 Strand London WC2R ORH Page 1 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 The trLJStees who are also directors of the charity for Ihe purrx)ses of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of A¢¢ounting and RetK>rting by Charities". Statement of Re¢ommended Practice applicable to charities preparing their accounts in accordan￿ with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 102) leffective 1 January 20191. The HPV and Anal Cancer Foundation Limrted is a Unf(ed Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America IUSAI (Chanty EIN= 27-32175201. which was estsblished April 2010. All work undertaken by the UK Foundat￿n is in collaboralion wth its parent. The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was estsblished through Its Articles of Asso¢iation. which established the objects and powers of the ¢h8ritsble company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA. The HPV and Anal Cancer Foundation board cx)nsists of four members. The directors are responsible for the legal, financial, program and management oversighl of the charity. The board held its annual meeting on December 27. The daily responsibilib.es and mission of the FOur￿atIOn are exeGuted by the lea￿S in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day acliwties. When the Trustees advertise for new board members, candidates are sourced from the general public as well as ¢onts¢ts of the ¢harity. A diverse mix of skilb and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trust￿$ are gwen a full introduction to the work of The HPV and Anal Cancer FoundatK>n in addth.on to copie5 of Ihe organizats"on's financial documents, bylaws, and policies. Page 2 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES Obje¢tive$ and alms History The Foundation was firsl established in the USA in 2010 by three siblings who kjsl their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limtted Iherapeutic and community support available to her, they created the organisation to fill the void caused by s(2nt public, suentrfic and medical focLJS on this disease and its cause, the human papillomawrus IHPVI. HPV causes anal cancer and at least five other ¢an¢ers, amounting to 50/¢ of ¢an¢ers woddwide. These cancers a￿ preventable. In 2012, the org8ni2ation expanded to the UK with 2013 as its first full operational year. Mission The HPV and Anal Can¢er Foundati￿ empowers anal ¢an¢er pab.ents and a¢¢elerates prevention and research methods that eliminate anal can￿r and the wnJs that causes the majority of cases, HPV. Objectives Highlight the relevance of human papillomavirus IHPVI in contracting can￿r,. Advocate for prevention melh(Kls that wll end anal cancer and HPV-related cancers, including gender-neutral vaccination- Accelerate a cure for the 5% of all Can￿rS that are caused by HPV, wth a f￿uS on anal cancer. and Providè support for sutwvors, caregivèrs, suèntsts and providèrs connÈctéd to anal can¢Èr. The Need A fundamental objective of the Foundation's ￿￿)r￿ is to reduce the inudence of anal cancer and other HPV-related cancers. HPV is a very common skin wms that nearty every sexLJalty active person will get at some point in their lives. HPV affects both men and women and is resp(￿sible for 5 /0 of the world's cancer burden. HPV cau$8S fAnoers of the anus. ￿[￿x. head and neck. ￿nIS. vagina. and vulva. Protection against HPV through unwersal HPV vaccinatK)n is a cribcal public heaAh goal. With HPV identified as a cause of six different types of cancer, and 5% of cxncer Gases worldwde, li is imperative that we protect the entire population against it. The most effective method to reduce Can￿rS related to HPV is to prevent in((ial infection of the virus through Immunisab"on. The Foundab"on achieves this important airll through its efforts to advance eqLJal access to HPV protection for tK>th boys and gitls through gender-neutral vaccination against the virus. At the Intr￿UCtion of the vaccine in most countries, onty girls were able lo receive this lrfe-sawng intervention Whi￿ boys were generally excluded. The Foundation created and the coalitions in the US and UK to ensure all children have equal access to protection against these Can￿rs. The US achieved the milestone of re￿MMendIng HPV protscb.on to all fjhiklren in 2011. Following the Foundation's five-year advocacy campaign in the UK, sch(K>l-based HPV vaccination for began in September 2019. Our focus now turns lo securing the same protection for W as well as gir15 across Europe. While we work lo prevent future cases. it is also fundamental ihat scienlific and medical disparities are addressed for the FK)pulalion that will continue lo be diagnosed wth HPV-related Can￿rS like anal cancer. Treatment optsons have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities [￿ed better research tools and investment in novel ideas to develop a Cure. The stigma surrounding anal cancer remains one of the ￿n1[al thallenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres prowde only limited information specrfic to the experien￿ of anal cancer. Many patients f*1 ISO￿ted and lack the support and educational resources that significantly improve quality of lrfe during and after treatment. Page 3 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 Strategies to Achieve Our Goals Wg a¢hievo our mission in the UK and US through ¢ol1at%>rati￿ wth scièntists, clinioans, survivors, organisations, and government agencies., education of stakeholders and the general public,. survivor support., and investment in the medical and scientific commurbity lo end HPV and the cancers il causes. Specrfically. we take action to destigmatize and raise awareness about HPV, HPV-relaled cancers, and anal cancer., increase access lo the HPV vaccine,. improve screening protou)Is and preventslive care., empower anal cancer thrivers," and accelerate a cure for anal cancer and other Hpv-￿18ted illnesses. Page 4 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES KEY ACHIEVEMENTS IN 2020 Foundation RestNcture In 2020 we continue OLJr two-pronged programmatic approach, operating under the umbrella ol The Anal Cancer Foundation (registered as The HPV and Anal Cancer Foundation Limf(ed in the UK). The Anal Cancer Foundation." Improve the lives of anal can￿r patients through prevention, treatment, and support. The NOMAN Campawjn: End 5% of the world's can￿r through gk)bal coverage of HPV immunisation for all children. NOMAN is an Island The NOMAN is an Island Campaign raises awa￿ne$S atK>Ut the HPV-rel*ed ¢an¢er epidemic in men and women and educates about the impx)rtance of universal HPV vaccination while challenging participants to extreme endurance ra￿5 across the worfd. It is through such extreme feats of athleticism that NOMEN honour thé struggle and isolation that many Cancer patients feèl. NOMAN has been an incredibly successful campaign. Since rts inaugural event in 2013 the B8rcelon8 Ibiza.. Row to End HPV, 141 individuals and their hundreds of supporters have embraced the cause and our values. These NOMEN have raised awareness about HPV-related cancers on a local, national, and international scale as well as funds to support our programmes. In 2020, NOMAN ride￿ lty)k on the Haule Route Venloux event. The Haute Roule is the worfd's most prestigious cycling event for amateur cyclists providing unparalleled experiences wth the key ingredients of 3 or 7 day professional road ra￿ng events in the most iconic cycling destiT)atK)ns wortdwde. In October, a team of NOMAN riders took on the Haute Route Ventoux, a May event comprising neady 300km of riding and 8000 metres of height gain, raising funds to prevent 5¥0 of cancer in the process. We are grateful for their extraordinary efforts lo raise awareness around HPV-relaled Gancers. Additionally a gTOUP of supporters in Geneva undert(x)k the inaugural 'An￿re$ Man for NOMAN. event tackling 1.5km of swimming. 49km of ¢y¢ling including 500m elevation gain, and a 13km run - all in the name of NOMAN'S mission to prevent 5% of cancers. We now look forward to the 2021 edition of our Barcelona - Ibiza.. Row to End HPV races, and the Haute Roule events of that summer. HPVAction HPV Action IHPVAI is a collaborative partnership of patient and professional organisations that are working to reduce the health burden of HPV. The HPV and Anal Can￿r Foundation was a founding member of HPVA in 2013 and has sin¢e provided financial supw>rt and leadership for the Coal￿On. Following a five-year campaign, the Foundation arKI its partners in HPV Action achieved a monumentsl milestone to end all HPV-related cancers with the adoptM)n of sc￿?0141aSed vaccinations for boys. Page 5 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES HPV causes 5% of Can￿rS worfdwide in men and women. At the end of 2019, around 40 countries vaccinate boys as well as gids. HPVA advocate5 equ81 acce55 to HPV proleclion for both ￿y5 ar￿ gids lo prevent a r8nge of HPV-rel8led conditions including cancers, precancers, and genital warts. HPVA'S efforts illustrated that boys should be included in the UK HPV immunisation program to protect.. 111 men and women from HPV-relaled anal, cervical, penile, oropharyngeal, vaginal and vulval cancers and p￿cancers.,{2l men and women from genital warts., and 131 children and adults from TecuThenl, respiratory papillomatosis IRRPI, a rare but disabling HPV-relaled condition. HPVA estimates that over 2.(K)O men a year in the UK develop a cancer Ipenile, anal or oropharyngeall caused by HPV and 5.0(K> women a year develop a cancer lanal, cervical, oropharyngeal, vaginal or vulvall caused by HPV. HPV additionalty causes 48,000 new cases in men and 39.000 cases in womén of genitsl warts annually. Approximately 600 aduhs and children in the UK hav& RRP. A national HPV vaccination programme that includes all children in the UK wll improve public health and health inequalities, prove cost*ffective and, above all, reduce the suffering caused by cancers and diseases that are easily preventable. As part of the HPVA group, we educate MPS, ministers, governments and NHS officials on the imwrtance of protecting all chI￿ren against the rarcinogenic HPV virus,. inform the public." build scientific support,. and engage patient. professK)nal and olher organisations in support of ending HPV and the cancers it causes. Prior lo 2019, HPV immunisation programmes in the UK were exclusively for females. wth girfs aged 12 and 13 routinely vacGinated predominantty a 5chool-based programme since 2007. Consgquently, men were nol protected againsl HPV. HPV infects bolh men and women, and causes cancer in both sexes, including cancers of the anus, cervix. head and neck. penis. vagina. and vulva. Many of these cancer cases are preventable if the person is immunised before they are expose(J to the wrus. HPV Actlon Impact 2020 Gender-neulral HPV va￿l￿ation began in September 2019. h¢)wever no announcement %WdS made as to whether a catch-up programme would be instigated for boys aged 1&18. In its meeting in earfy Febnjary 2020, the JCVI decided not to recommend a c2tch-up vaccination programme for older boys. HPV Action did as much as we could to advocate for a catch-up programme despite our limited capacity including meeting wrth JCVIIPHE in January 2020. wrreswndence with JCVI, the engagement of several MPS who wrote letters to minislers and tabled PQS, and a social media campaign through twitter and FaceLK)ok. Whilst this was a disappointing outcome it was felt that it was not worth Continuing with this effort because it was extremely unlikely that JCVI would change its mind, especially in the contexl of the global vaccine shortage (predicted to last until 20231. In March 2020 the fulure of HPV ActKJn was discussed vthich tTh)k account of the achievement of the universal programme, the recent JCVI decision on a catch-up programme for boys, and the new ECCO HPV in(tiative. 11 w85 8greed that HPVA would be wound up in September. wrth the Jab5 for the Boys website to continue as a legacy project. Numerous HPV Actson members agreed lo stay on a daiabase so Ihat they can if necessary be contacted if an issue wth vaccination arises in the future. such as a f811 in uptske due to anty'_vaccination campaigning. A broad-based campaign in this vein played a key rde in reversing a fall in vaccination uptake in Ireland in recent years. Several members are involved in the European HPV Action Netr￿rk which aims to eliminate HPV cancers in the 53 mernber ststes of the WHO European region. Coalition Building The $1 organisations in the membership of HPV Action. induded= Page 6 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES British Association for Sexual Heatth and HIV, British Ass¢xialion of Dental Nurses, British Association of Dèntal Therapists, British Dental Assoaation, Btitish Society lor Immunobgy, British Society of Dèntal Hygiene and Therapy, Br￿k, Cancer Focus Northern Ireland, Children's HIV Association of the UK & Ireland ICHIVAI, ENT UK. European Men's Heath Forum. Faculty of General Dentsl Practice IUKI.FaGulty of Public Health, Faculty of Sexual and Reproductive Healthcare, Family Planning Association, GMFA IGay Men's Health Charity), Herpes Viruses Association. HPV arKI Anal Cancer Foundation, Lefs Talk About Mouth Cancer, London Cancer ￿liance, London Friend, Men's Heath Forum IGB), Men's Health ForLJm Ireland, Mouth Cancer Foundation, National Aids Manual, National As￿)ciation of Laryngectomee Clubs INALCI, National Education Union, National Oral Health Promotion Group. National Union of Students, Northern Head and Neck Cancer Fund, Oral Cancer Foundation IUSA}, Oral Health Foundation, Primary Care Urology Society, Rainbow Project, Reprc￿uc1lve Health Matters, Royal College of Obstetricians and Gynaecologists, Royal Society for Public Health, The School and Public Health Nurses Association, Sexpression.'UK, Society of British Dental Nurses, Society of Sexual Health Advisers. Stonewall, The Swallows Head and Neck Cancer Support Group. Tenovus. Terre￿￿ Higgins Trust. Thro81 Can￿r Foundation. The Urology Foundation, and Wellbeing of Women. HPV Actlon Europ8 Nètwotl( In 2018 and 2019. the Foundation was involved in discussions to eslabli5h an adv(Yocy ¢ampaign in Europe lo Introdu￿ gender-neutral vaccination across the region and completely eliminate HPV-related diseases. NOMAN has partnered with the European Can￿r Organisation to achieve this mission. The European Cancer Organisation works to reduce the burden of cancer and improve outcomes and the quality of care for cancer patients through mulb'disciplinary and mulb"-professionalisrn. As the not-for-profit federation of member organisations working in can￿r at a European level, they convene oncology professionals and patients to agree on policy, advocate for wsitive change. and be the united v0￿e of the European cancer communty. Together wth the European Cancer Organisation, the FcKJndation I￿kS lo￿ard to working European policy makers to end the suffering caused by HPV cancers. The main achievements of the HPV Acljon in 2020 were as follows: Launch of new HPV report.. Viral Protection: Achieving the Possible In October we launched a major new report viral Protertion". knhieving the Po55ible. A Four Step Plan for Eliminating HPV Cancers in Europe. calling for a series of goals in order to prevent 67,500 cancer cases per year across the 27 EU member stsles, rising to 90.(W across the wider World Health Organisalion IWHOI European region. The ¢entral re¢ommendation of our plan to eliminatè HPV Cancets in Europe is as follows.. The European Union and the wider WHO Euro[￿8￿ region should commit lo the core goal of matching and exceeding the WHO Global Strategy for Cervical Cancer Elimination and implement poliryes and strategies for the elimination of all the cancers and diseases caused by HPV.. Action areas to achieve this goal are= 1. Universal lor'gender-neutral'l HPV vaccination for adolescents and optimal levels of uptake. 2. National organised KK)pulation-based Ce￿￿1 ¢an¢er $c￿nIng Kryrammes using HPV testing systems and with higher levels of uptake. 3. Cancer treatments ¢onsistendy and equitably offered in line wth best practice guidelines and ¢are and support that rnaximises patients. quality of lrfe. Page 7 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES 4. Action to improve public and professv)nal awareness arvj education about HPV in order lo improve va¢cination and sereèning uptaké. We believe that the WHO'S strategy for the gloli81 elimination of ceNcal cancer 8$ a public he8llh problem, is not ambitious enough. The forthcoming Europe Beating Cancer Plan, EU Cancer MissK)n and EU4Health Programme must include actions lo eliminate all HPV can￿rs. The world has used vaccines lo eliminate the suffering caused by many diseases such as sMall￿>X and rK>lio - it is time we add HPV and the suffering it causes to this list. The HPV Action Network urges Europe to make HPV cancer elimination a fom)al European shared goal. Europe's Beating Cancer Plan and other RegionaVEUINational initiatives present significant opportunities for progr8SS to bè madé. Viral Protèction highlights that: . A quarter114 out of 54. 260/0) of European region countrie5 sb"Il do not V8cun8te gids against HPV. Under a half126 countries, 48Y.I vaccinale, or are plannirwj to start vaccinaiing. boys as well as girfs. . Few countries meet the bmdely-accepled target of 80°A HPV vacanatM)n coverage. 16 countries have 'opw)rtunistic' cervical cancer screening whith means their success depends on the in((iative of individual women and their d(￿s. reSu￿ng in lower uptake. Treatmenl outcomes for cancers caused by HPV vary widely across the region., for women diagnosed with cervical cancer, five-year survival rates range from 80.kn in Ice￿nd lo 55% in Poland and Bulgaria. 'Fake news, about HPV vaccination safety, widely shared via social media. has resujied in falls in uptake,. in Denmark. it fell from 90% to 540k. You can read the ￿an below, and find out more the campaign here. The report vras distributed lo key DG Sante officials, MEPS and other health stakeholders. Europèan Canc•r Summlt NOMAN co-founder Tristsn Almada was invrted to address the European Cancer Summit on the role of civil soaety organisations in the fight to eliminate HPV Cancers in Europe, refiecting on the success of our campaign in the USA and UK to extend HPV vaccination programmes to include boys as well as girfs. Speaking alongside Professor Margaret Stanley, Emilie Karafakilis and Cobi Reksman. topics induded public health needs, the possibiltty of an HPV Cancer free Europe by 2030. and tackling vacryne hesitancy. The following resolutions were passed at the summit by attendees, followng the session.. Resolution 1- Screening 'Immediate and urgent action should be taken to ensure thal cetvical ￿nCer screening programmes are not interrupted by COVID-19, especialty in countries wth the bwest screening rates. The adoption of HPV self-sampling must be a￿l￿￿ed in order to improve uptske.. Resolution 2- Vaccination 'HPV-associated cancers are preventable by universal vaccination. Anti-vaccination misinformation is putting programmes at serious risk and all European hea￿ authoribes must act now to imwove public Confidence in HPV vaccination." Page 8 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES Other milestones included Presenl8tion on HPV to ENVI Heath Working Gr¢xJp118 February 20201 Presentation to IPVS Conference124 July 2020} Meeting on HPV and Europe's Beating Cancer Plan with Matthias Schuppe. DG Sanle129 Juty 20201 P￿Sentation to the BECA Committee, EU Parfiament {2 December) Increased stakeholder engagement in Nelwork The Network now has 21 memberslstakeholders. shown here.. https'.l/www.europeancancer.orgltopic-nelworks11:hpv-action.html. We now await the publication of the Bealing car￿er Plan to see rf actM)ns on HPV have been induded. Anal Cancer Foundation Anal cancer is one of the fastest growng Can￿rS in the United States, and steadily in¢reasing in the United Kingdom. We continue to work tirelessly to make life belier f(x families faang anal cancer through our programs lo raise awareness. accelerate eady detection. improve quality of lrfe. and advance a ¢ure. This year, we made incredible progress raising awareness atrx)ut the need to reforni how anal cancer thrivers are diagnosed and treated. Peer to Peer Support Progr4mme and Thriver Edu¢ation In the UK, about 1,500 people, and in the US, about 8,600 are diagnosed wth anal cancer annually. Anal cancer incidence is increasing and affects more people across the wodd every year. The social stigma that anal cancer carries with il prevents fair and equiiable conversabon. awareness. and funding to supwrt research and care for people with the disease. Support and information is limited for anal cancer thrivers lour word for survivors) and rnany thrivers never mtrèt anothèr anal canGer patiént. The Foundation provides educ2tional forums and a pèer mentoring program to support thrivers to close this gap. The Peer to Peer supwrt program is a free service provided by the Foundation in the UK and USA to connect path.ents and caregiver5 facing the challenges brought on by anal ¢an¢er wth a peer who has undertaken the same journey. Connections are available for anyone at any cancer stage from newly dragr￿Sed to years after treatment. Volunteers listen and help thrivers through iheir ￿nCer joumey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal rancer and give surwvors a Vol￿ and a community. The program also matches caregivers together. At the end of 2020. the HPVACF'S Peer-to-Peer programme included 558 participants. Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You.. Managing Side Effects From Treatment For Anal Cancerf event, featuring expert dinicians who treat people living with anal can￿r as well as a panel of thrivers has been viewed by over 4000 people by the end of 2020. 'Living and Thriving After Treatment for Anal Cancer. Addressing Long Term Side Effects.. wa5 viewed 81KK) limes by the end of the year. Intemational Anal Neoplasia Society IIANSI IANS, the International Anal Neoplasia Medical Society. create5 medical guidelines and supports research essential to preventing and treating anal cancer. LANS was creaied with a seed grant from the Foundation. Page 9 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES IANS mission is to provide a forum for individuals with a bn)ad spectrum of background, Mewpoints and g&￿raphiC origin, an 8xchangÈ of ideas and dissemination of kno￿edge regarding the pathogenèsis, diagnosis, treatment and prevention of anal neoplasia. In support of this mission ￿S= Develop rK)sition papers warding the path(¥Jenesis, diagnosis. treatrnent and prevention of anal neoplasia. Represent the consensus opinion of IANS regarding the above topics lo other Professional societies, public organizations, regulatory authorities and govemmental bodies. Encourag& the devek)pment of a robust ￿$￿a[ch agenda on the pathnnections to other pab.ents and caregivers through our Peer to Peer support programme. Our goal in 2020 continues to be ensuring rnore anal cancer thrivers have access to the infomiation they need to face their ¢an¢er joumey through tsrgeted outrea¢h based on our exisb.ng supporter base and a newsletter series for patients and caregivers, fctused on our expert and popular resources. With thè pandèmic reduang the in person resources available to the anal cancer community, the nééd for communication wth our community was more imporlant than ever. Our communicatK)ns strategy focused on consistency and 'being useful., wth content covering treatment and research updates. stories from community members, and explainers of our setvices and how we suprx)rt the anal cancer community. The resuts spoke for themselves. Page 10 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES A 17 /0 increase in visitor sessions online A 15Q/¢ increasè in the num￿[ of pagès sèssion An 8 /0 decrease in single page sessions A 2.50k increase in sessions per user Going forward, we aim to continue prowding all the suppNt the anal can￿r community needs. Investing in ¢ures= financing ground-breaking re$ear¢h As a non-profit funder of medical research molivaled by personal k)ss, our mission is to offer new treatments to patients as quickly as FK)ssible. Our research philosophy is lo invest in high-ri5k. high-reward projects that we believe hold tremendous promise for advancing the treatment field for anal cancer patients and other pab'ents living wth HPV-related cancers. We accomplish this by aligning incentives across all of the relevant stakeholders, fostering collaboration wherever possible, receiving input from a board of key opinion leaders and expert advisor5, and using funding to address resource gaps in p￿InIcal and clini(21 settings. We collaborate with other foundations and government agencies to ensure funding for the research that we seek to advance. These partnerships have allowed us to leverage our fund5 to pr[xju￿ faster and more robust researth outcomes to urgently find a cure. The Foundation's mission is focused on improving the lives of hvo cancer populations specrfically.. people facing HPV-related cancers and people facing anal cancer lone type of HPV-related can￿rI. Six years ago, pèople who were diagnosed wth these rAncets in a late stage had few therapeutic options available to them. For anal cancer, no significant update to advanced CAncer treatment had occurred in four decades. For HPV-relaled cancers, there were no Clinical￿ recognized trials seeking one therapy to treat the different4)ut-connected cancers simuhaneously. With a few focused grants, the Foundation sought to raise the profile of Ihese can￿Ts, increase inlerest among the saentific community, spur innovative research, and delpier new drugs into the hands of patients. The Foundation chose lo invest in an emerging approach to the fight against cancer= immunotherapy. Cancer, in essence, is a failLJre of the immune sy8tem to "see" and dismantle abnomial cells. This breakdown albws one or muf(iple errant ￿lIS to Multip￿ until they affecl the functioning of the body. Immunotherapies seek to address this rnalfuncb.on by m¢xlulab"ng spectfic aspects of Ihe immune syslem to tsrget can￿r cells. Supporting RèsÈareh to Find A Curè for multip￿ HPV*ÈlatÈd Cancè HPv-re￿led cancers represent SW. of the world's cancers and treatment to cure these rllalignancies has barely advanced in decadès. To add￿sS this vast and unmet need, the Foundation partnered VAth Stand Up To Cancer and the Farrah Fawcett Foundation in a $1.2 million grant to support researchers at Dana-Farber Cancer Institute in Boslon, Ma55achusetts, vtho are irwesb"galing the treatment of HPV-relaled canGer by harnessing the immune system against it. The study was a first of its kind as we sought a therapy to help multiple HPV-related cancers, instead of addressing each cancer individualty. The sludy focuses on the preclinical and clinical development ol an immunotherapy Ireatment for patients wrth recurrent HPV-related anal. cervical, and head and neck cancers who have relapsed after their initial therapy as such patients have few therapeutic oplions available lo them. A successfLJI vaccine would be used to augment chemotherapeutic outcomes and improve Surwval. Specifically, this Phase 1 b12 trial tests tumor response and safetylefficacy of vaccination with E711-19 nanomer for the t￿atment of incurable HPV-16 related head & neck, cervical, and anal can￿r in HLA-A2 ￿sth'Ve patienis. It investigates the theory of therapeutic CD8 vaccines against HPV epf(opes. This project is W by Ellis L. Reinherz, M.D., Chief of the Laboratory of Immunobiology and Co-Dire¢tor of the Cancer Va¢¢ine Center at Dana-Farber and Robert l. Haddad, M.D., Disease Center Leader for Head and Neck Ooncology at Dana-Farber. Page11 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES The trial was completed in 2019 and resulted in three publications. Whilst the trial agent produced no durable responsè in study participants, rèsearchers StUd￿ng the resuts wèie ablé to gain a better understanding of the diversity of cancer cells in HPV cancers as well as why certain HPV therapeutic vaccines might fail. Additionally, the tri81 improved care in the HPV can￿r space by creating connections among HPV laboratory and clinical investigators across the Boston research community, and more broadly, across the national HPV advocacy communty. As the first trial lo investigate a IherapEulic vaccine for mU￿1Ple HPV cancers. it was a critical first step towards unif￿ng a once-siloed research community to find a cure for all HPV cancers. As a result, where once each HPV cancer was researched solely in individual trials. Ihere are now multiple clinical trials specifically researching agents to treat and cure all HPV Can￿rs. Encouraging the scientific field to view these cancers comprehensNely resutted in a new approach for gèn8rating promising treatments on behalf of the hundreds of thousands of people living with HPV-rèlatéd cancers. In light of this significant shift led by the Foundation, there are now several phase l and 11 trials underway that seek to find a treatment for Multip￿ HPV-related cancers al the same lime. LOOKING AHEAD: 2021 As we Iwk ahead. the HPV and Anal Cancer Foundati(￿ Continues to seek the most effective methods to prevent HPV and cure the cancers it causes. The Foundation wll continue to work tirelessly to eradicate all HPV-related cancers by furthering public wlicy and scientific debate, eliciting further professional and expert supwrt, encouraging the development of regional initiatives on vaccinating bo￿. and demonstrating why it is important to protect all children against HPV at the recommended age. Although the UK b￿an vaccinating boys against HPV as pupils retum to schools in September 2019, we will continue to work with Public Heatth England and other Stake￿)lderS in the HPV-related disease space to ensure that uptake for this cancer-prevenb.ng intervention among 12-13 year old boys is as high as possible. The interruplion caused by the pandemic wll undoubledly affecl vaccination rates in the UK and beyond. In the wake of a growng vaccine hesitancy senlimenl. our work is more important than ever. Our advocacy focus now turns trjwards tMJikJing our nascent partnership with the European Cancer Organisabon and the HPV Action Network in order to achieve change across the European wntinent. The EU Beating Cancer Plan set to be announced in 2021 ￿11 a￿d￿sS cancer-related inequalities between and within Member States with actions to supw)rt, coordinate. and complement Member States, efforts. With over 40 /. of ¢an¢ers in the region preventsble, the extension of HPV va¢¢inatKJn programmes to prote¢t boys as well as girls provides a recognised and effective means to tackle cancer. Through the NOMAN is an Island Campaign, collatrx)rations wth adV(￿teS and legislators, media attention and athleb'c event participation, a broader audience is understanding the importance of protecting all children against HPV_ With the NOMAN side of the organisation leading on HPV-related adivities. our platform is growing from which to broadcast our message. In 2021, we wll continue lo partner with ihe Haute Route on further cycling events as their European Charity Pather. furthering the reach of our message to prevent 5 /. of cancer, and providing the opportunity to reconnect with the cyclists wthin our community. Additionalty, the return of our flagship Bar￿Iona - Ibiza.. Row to End HPV races will as ever, capture the imagination of, and spread the message ol how we can ￿￿vent HPV ¢an¢ers, to a broader audience. We remain committed to finding better cures for patients and creating the essential research building blocks that currently do not exist. For four de(2des. tréatment for all stages of anal cAncer had remained essentially Ihe same with no FDA-approved drugs targeted and the same toxic side effects as in the 1970's. Our breakthrough with MD Anderson Cancer Center is offering new hope to anal Gancer p8lien15 and we look forward to ftjrther progress in the search for a cure. Page 12 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 OBJECTIVES AND ACTMTIES We will continue lo provide anal cancer thrivers information and supw)rt they need on their journey. In addition, our Pèèr to Peer support programme relains its importance in supporting and empowering anal cancer survivors and caregivers. Utiliing digital and live platfomis, we will reach a wider protx)rtion of the anal cancer communty, enabling patients to gain answers to the concems they have and lo conned lo other anal cancer patient experien￿. We thank all of our donors and look forward to continuing the mission to eM￿r anal cancer patients and accelerate prevention and research methcNJs that eliminate anal cancer and the virus that causes the majority of cases, HPV. Publi¢ beneflt The truslees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when revieb*ing the charivs aims arHJ objectives and in planning future activities. FINANCIAL REVIEW Financial position It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organization. The ￿VenUe for the charity is dependent on donab"on5 from the public. Income for the UK HPV and Anal Cancer Foundation in 2020 was £90,186 and expenditure was £129,268. Reserves policy The reserves policy is to maintsin a minimum that énatles the organisation lo meet its finan¢ial ¢ommitments for the year, including grants, conlracts. and staff salaries. Going concern As staled in note 20, the Trustees have consvjered the effect of the COVID-19 pandemic. The Trustees consider that the pandemic is likely to cause disnjption to the Charitys activ￿eS but a￿ confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twélve months from the date of approval of these financial statèments as well as for the foreseeable future. STRUCTURE, GOVERNANCE AND MANAGEMENT Goveming do¢ument. $tru¢ture and management The charity is controlled by its governing document, a deed of trust. and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. Page 13 THE HPV AND ANAL CANCER FOUNDATION LIMITED Report of the Trustees for the Year Ended 31 December 2020 The HPV and Anal Cancer Foundation Limrted is a United Kingdom IUKI subsidiary of The HPV and Anal Cancer Foundation in the United States of America {USA) {Charity EIN= 27-32175201, which was established April 2010. All work undertaken by the UK Foundation is in colla￿ratiOn with ils parent. The HPV and Anal Can￿r Foundation Limiled is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charrty on the 25 May 2012. The company was estsblished through its Articles of Association, vthich established the objecis and powers of the charitab￿ company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA. The HPV and Anal Cancer Foundation board consists of four members. The Trustees are responsible for the legal, financial, program and management oversight of the charty. The board held ils annual meeting on December 21. The daily ￿spOnSibl11tieS and mission of the Foundation a￿ execLJted by the teams in the USA and the UK. In the latter, the Director of UK Operations is resw)nsible for the coordination of day-tcFday actiMb"es. When the Trustees advertise for new iM)ard members. candidates are sourced from the general public as well as coniacts of the charity. A diverse mix of skills and backgrounds a￿ sought. Prospective trustees are interviewed prior to appointment. As part of their induclion, new trustees are gwen a full introduction to the work of The HPV and Anal Cancer FwndatK>n In a￿d￿"on to copie5 of the ofganizab"on's financial documents, bylaws and wliaes. Risk management The trustees have a duty to identify and review the risks to whith the charity is exposed and lo ensure appropriate controls are in pla￿ to prowde reasonable assurance against fraud and error.The trustees of the Foundation hold the responsibility of safeguarding the chartys assets and systems are in place lo mttigale those risks which the charity may fa￿. This report has been prepared in ac(x)r(lance wth the 5peryal provision5 of Part 15 of the Companie5 Act 2006 relating to small companies. Approved by order of the tM)ard of trustees on . 27.09.2021 . and signed on its behaK by. /AL /¥L- T Ajmada - Trustee Page 14 Indep8nd8nt Examln8r's Report to thè Trusts•s of The HPV and Anal Cancer Foundation Limited Independent axamlnar's report to the trustees of The HPV and Anal Cancer Foundation Llmlted llhe Company'l I report lo the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2020. Re5pon5ibilities and ba515 of report As the charity's trustees of the Company land also its directors for the purposes of company lawl you are responsible for the preparation of the accounts in accordance the requirements of the Companies Act 20061.the 2006 A¢VI. Having satisfied myseff that the accounts of the C¢ynpany are not requirwj lo be audited under Part 16 of the 2006 Act and are éligible for indepèndènt examination. I rèp(wt in rèspect of my éxamination of your oharitls accounts as carried out under section 145 of the Charities Act 2011 1.the 2011 Act'}. In carrying out my exarninalion I have folbwed the Directions given by the Charty Commission under section 145151 Ibl of the 2011 Act. Independent examiner's statement I have completed my examination. I cx)nfirni that matters have come lo my attention in connection wlh the examination giving me cause to believe- accounting records were not kept in reS￿t of the Company as required by section 386 of the 2006 Act", or the accounts do not accord with those records., or the accounts do not comply wrth th8 a¢¢ounting réquirements of secb.￿l 396 of thè 2006 Act other than any requirement that the accounts give a Irue and fair view which is not a matter considered as part of an independent examination., or the accounts have not been prepared in accordance ￿th the methods and principles of the Statement of Recommended Practice for accounting and rerx)rts"ng by charities (applicable to charities preparing their accounts in accordance with the Financial Reporb"ng Standard applicable in the UK and Republi¢ ol Ireland IFRS 10211. I hava no concèms and have come across no othèr matters in connection with thè èxamination to which attention should be dravm in this repcvl in order to enable a proper understanding of the accounts to be reachéd. Richard Billinghurst FCA Knox Cropper LLP Chartered Accountants 65 Leadenh811 Street London EC3A 2AD 2810912021 Dale.. Page 15 THE HPV AND ANAL CANCER FOUNDATION LIMITED Statement of Financial Activities (Inco￿oratIng an Income and Expenditure Account) for tha Yèar Endèd 31 D￿M￿r 2020 2020 Total funds 2019 Total funds Unrestricted fund5 Reslricted funds Notes INCOME AND ENDOWMENTS FROM Donations and legacies 17.061 17.061 11,790 Other trading activities Investment income 73,105 73,105 20 428,398 55 Totsl 90.186 90.1B6 440,243 EXPEND￿uRE ON Raising funds 20,478 20.478 147.779 Charitable activitiès Care and Support Awareness Raising Research for a Cure 27A17 76,467 4.906 27.417 76,467 4.906 8,664 187,219 3.828 Totsl 129.268 129.268 347,490 NET INCOMEIIExPEND￿URE} 139.0821 {39,082} 92,753 RECONCILIATION OF FUNDS Totsl fvnds brought formard 153.171 13.11)0 166.271 73,518 TOTAL FUNDS CARRIED FORWARD 114.089 13.11JO 127.189 166,271 The notes fonn part of these financial statements Page 16 THE HPV AND ANAL CANCER FOUNDATION LIMITED (REGISTERED NUMBER.. 079554511 Balance Sheet 31 December 2020 2020 2019 Notes CURRENT ASSETS Debtors Cash at bank 14 218 135.806 11,999 160,983 136.024 172,982 CREDITORS Amounts falling due within one year 15 {8.835} 16,7111 NET CURRENT ASSETS 127.189 166,271 TOTAL ASSETS LESS CURRENT LIABILITIES 127.1B9 166,271 NET ASSETS 127,189 166,271 FUNDS Unrestricted funds Restricted funds 18 114,089 13,100 153,171 13.100 TOTAL FUNDS 127,189 166,271 The charitable company is entiued to exemption from audit under Section 477 01 the Companies Act 2006 for the year ended 31 D￿mber 2020. The members have not required the company lo obtain an audit of r(s financial statements for the year ended 31 December 2020 in acwrdance 476 of the C(Mnpanies Act 2006. The trustees acknowledge their responsibil((ies f¢x lal ensuring ihat the chariiable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial slateTnenls which gwe a true and fair view of the state of affairs of the charitable company as at the end ol each financial year and of its surplus or defiat for each financial year in accordance wrth the requirements of secb.ons 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating lo financial statements. so far as applicable to the charitsble company. Ibl These finanoal siatemenis have b*n prepared in accordan￿ with the provisions applicable to charitable companies subject to the small companies regime. The financial statements were approved by the Board of Trust*s and aulhorised for issue on .27.0&2021 . and were signed on rts behaw by. T Amada- Trustee The notes fonn part of these financial statements Page 17 THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements for the Year Ended 31 December 2020 ACCOUNTING POLICIES Basis of preparing the financial statements The financial statements of the charitable company. which is a public benefit entity under FRS 102, have been prepared in accordance with the Charibes SORP {FRS 1021 'Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to char(ties preparing their accounts in a¢¢ordan¢e wth the Finan¢ial Reporting Stsndard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191., Financial Re￿)rting Standard 102 The Financial Repo￿ng Standard applicable in the UK and Republic of Ireland. and the Companies Act 2006. The financial statements have been prepared under the historiral cost convention. Golng Concem The trustees consider that there are no material uncertainties about the Charitys ability to continue as a going concem. Financial r•parting standard 102- réduc￿ disclosuts èxèmptions The charitable company has taken advantage ol the following disck)sure exemptions in preparing these financial staternents, as pemiitted by FRS 102 The Financial Retx)rting Standard applicable in the UK and Republi¢ of Ireland.: the requirements of secb.on 7 Stslement of Cash Fbws. Ineamè All income is recognised in the Statement of Financial Activilies once the charity has entidement to the funds. it is probable that the Income wll be r￿1Ved and the amount can be measured reliably. Expenditure Liabilities aré racognis￿ as expenditure as soon as there is a legal or constructivè obligation committing the charity to that expenditure. it is probable that a transfer of economic benefits wll be réquired in setllemènt and thè amount of the obligab.on cAn be measured reliably. ExpenditLJre is accounted for on an accruals basis and has been classified under headings that aggregate all cost related lo the category. Where costs cannot be directly attribuleil to particular headings they have been allocated to activities on a basis consistent ￿1h the use of resources. Grants offered subject to condttions whith have not been met al the year end date are noted as a commitment but not accrued as expendiiure. Tangible fixed assets Depreciation is provided at the folkjwng annual rates in order to write off each asset over its estimate useful lrfe. (kean rowing tK)at and accessories- over 3 years Taxation The charty is exempl from corpL)ration tax on its charitable aclivtties. Fund accounting Unrestricted funds can be used in accordan￿ with the charilable objectives at the discretion of the trustees. Restricted funds can only be used for parbcular restricted purrM)ses within the objecis of the charity. Restrictions arise when specjfied by the donor LW when funds are raised foi particular restrKted purposes. Page 18 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 ACCOUNTING POLICIES- continued Fund accounting Further explanation of the nature and purwjse of each fund is induded in the notes to the financial statements. Penslon costs and other post-retlrement beneffts The charitable company operates a defined contribution pensv)n scheme. Contributions payable lo the charitable ¢ompanls pension scheme a￿ Charged lo Ihe Statement of Financial A¢b"vrties in the period to which they relate. Judgments and key sources of estimation uncertainty No judgement (apart frorll those involving estimatesl have been made in Ihe prc￿sS of applwng the above a¢¢ounting w>I￿leS that have a significant effect on amounts ￿CognIsed in the financial statements. OTHER TRADING AcT￿￿lEs 2020 2019 Fundraising events 73,105 428,398 INVESTMENT INCOME 2020 2019 Dew)sit account interest 20 55 RAISING FUNDS Ralslng donatlons and l•gaci•s 2020 2019 Staff costs Development expenses Marketing Miscellaneous expenses Donor software subscription Evenl Expenses Média Support Costs IOperats"ng) 5,611 152 638 9,318 49 1.896 117,494 4,149 14,235 1,174 4,226 3,300 6,015 20,478 147,Tt9 Page 19 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 CHARITABLE ACTMTIES COSTS Grant fvnding of activities (see note 71 Direct Cost5 (see note 61 Suptx)rt costs (see note 8) Totals Care and Support Awareness Raising Research for a Cure 23.114 36,094 863 4.303 27,138 4,043 27,417 76,467 4,906 13.235 60,071 13,235 35,484 108,790 DIRECT COSTS OF CHAR￿ABLE ACTIv￿lEs 2020 2019 staff costs Development Expenses M8rketing Miscellaneous Expense Event Expenses Media Inlernel and Website 15,713 6,642 12,939 806 4,226 13,200 6,545 640 9.318 49 117,496 16,597 60,071 144,100 GRANTS PAYABLE 2020 2019 Awareness Raising 13,235 7,963 The total grants paid to institutions during the year was as follows.. 2020 2019 ECCO Oral Health Foundation 13,235 6,963 1,000 13,235 7,963 Page 20 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 SUPPORT COSTS Governan costs Finan Other Totals Raising donab'ons and legacies Care and Support Awareness Raising Research for a Cure 5.191 3,776 25,423 3.812 779 499 1,623 219 6.015 4,303 27,138 4,043 28 92 12 177 38.202 3,120 41.499 Support costs, included in the atrx)ve. are as folk)ws.' Raising donations and legaues Care and Support Awareness Raising Bank ¢harges Wages Pensions Rent and Rates Insuran Fees and subscriptions Telephone, printing, postage and stationery SundriÈs Travel and M￿tingS Consultancy fees Conference expenses Independent Examinerfs fee Accountancy and legal fees 28 92 14,174 2.S20 4.465 127 215 1.212 2.147 61 103 776 1,374 39 66 65 133 53 870 400 422 77 210 433 53 2,828 398 1.373 250 207 6.015 4,303 27.138 2020 2019 Research fora Cure Total activities Total activities Bank charges Wages Pensions Rent and Rates Insurance Fees and subs¢riptions Telephone, printing, postage and stationery Sundries Travel and M￿tingS Consultancy fees 12 177 16,082 4,847 8,587 244 413 422 35.763 4,478 8,192 40 449 339 17 28 404 831 159 5,439 870 418 3,512 4.420 381 Carried forward 3,426 37,183 58,564 Page 21 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 SUPPORT COSTS- continued 2020 2019 Research Total 8¢tivilies Total activities Cure Brought forward Conference expenses Independent Examinerfs fee Accountancy and legal fees 3,426 37,183 1,196 2,640 58,564 193 2,645 185 41,499 61,883 NET INCoMEI{EXPEND￿vRE) Net in¢omellexpenditurel is ststed after ¢hargingllcrediting)'. 2020 2019 Independent Examiner's fee 3,000 2,640 10. TRUSTEES. REMUNERATION AND BENEFITS There were no Iruslees. remuneration or other beneffts for the year ended 31 December 2020 nor for the year ended 31 December 2019. Trustees. expenses Thérè wérè no trustÈÈs' exwnses paid for the year ended 31 D¢¢Èm￿r 2020 nor for the year ended 31 December 2019. 11. STAFF COSTS 2020 2019 Wages and salaries Oiher pension costs 37,406 4,847 35,763 4,478 42,253 40,241 The average monthly number of employees during the year was as follows.. 2020 2019 Average monthty employees No employees received emoluments in ex￿$ of £60.CNJ). The key management personnel of the charty are those persons hawng authority and responsibility for planning, d1￿ctIng and controlling the activities of the charity, diredy or indiredy, including any trustee ol the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management t￿rSonnel in the ￿riod amounted to £37.406 12019.. £35,763). Page 22 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL AcTIV￿lEs Unrestricted funds Reslricled funds Total funds INCOME AND ENDOWMENTS FROM Donations and legacies 11,790 11,790 Other trading activities Investrnenl income 428,398 55 428,398 55 Total 440,243 440,243 EXPENDITURE ON Raising funds 147,779 147,779 Charitable actiwties Care and Support Awareness Raising Research for a Cure 8,664 187,219 3,828 8,664 187,219 3,828 Total 347,490 347,490 NET INCOME 92,753 92,753 RECONCILIATION OF FUNDS Total funds brought forward 60,418 13,100 73,518 TOTAL FUNDS CARRIED FORWARD 153,171 13,100 166,271 13. TANGIBLE FIXED ASSETS Plant and machinery COST At 1 January 2020 and 31 December 2020 47.250 DEPRECIATION At 1 January 2020 and 31 December 2020 47.250 NET BOOKVALUE At 31 December 2020 At 31 De￿mber 2019 Page 23 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 14. DEBTORS.. AMOUNTS FALLING DUE W￿H1N ONE YEAR 2020 2019 Gift aid recoverable Prepayments 11,528 471 218 218 11,999 15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2020 2019 Social security and other tsxes Accrued expenses 5,835 3,000 4,071 2,640 8,835 6,711 16. LEASING AGREEMENTS Minimum lease payments under nOn-Can￿lIable operating leases fall due as follows.. 2020 2019 Within one year 1,925 17. ANALYSIS OF NET AsS￿s BEfwEEN FUNDS 2020 Totsl funds 2019 Total funds Unrestricted Restrict￿1 funds funds Current assets Current liabilities 122,924 (8,8351 13,100 136,024 18,8351 172.982 16,711} 114,089 13,100 127,189 166,271 18. MOVEMENT IN FUNDS Net movement in funds At 31.12.20 Al 1.1.20 Unrestricted funds General fund 153.171 139,0821 114.089 Restricted funds Research for a Cure 13.100 13.100 TOTAL FUNDS 166.271 139,0821 127.189 Page 24 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 18. MOVEMENT IN FUNDS- continued Nèt movement in funds, in¢luded in the above are as folk)ws'. Incoming resour Resources expended Movement in funds Unrestricted funds General fund 90.186 1129,2681 (39,0821 TOTAL FUNDS 90.186 1129,2681 (39.0821 Comparativ¢$ for movement in funds Net movement in funds At 31.12.19 At 1.1.19 Unrestricted funds General fund 60.418 92,753 153,171 Restri¢ted funds Research for a Cure 13.1¢J) 13,100 TOTAL FUNDS 73.518 92.753 166.271 Comp8r¥live net movement in furKls, included in the above are as folknvs.. Incoming resources Resources expended Movement in funds Unrè$trfct•d funds General fund 440,243 1347,4901 92,753 TOTAL FUNDS 440.243 1347,4901 92,753 Capital fund The HPV and Anal Can￿r Foundation Limiteil has shareholder capital equal lo £1 and is owned by HPV and Anal Cancer Foundation. a registered charity in the United States of America, EIN 27-3217520. Research for a Cure Fund The fund was sel up lo award grants lo researth which wll advan￿ devek)pment of effective treatments for anal and all HPV-relaled Ggncers. Page 25 ¢ontinued... THE HPV AND ANAL CANCER FOUNDATION LIMITED Notes to the Financial Statements- continued for the Year Ended 31 December 2020 19. RELATED PARTY DISCLOSURES There were no rèlated paty transactions for the ￿ar ènded 31 Dwmber 2020. 20. GOING CONCERN The Trustees have ¢onsidered the effect of the COVID-19 pandemic in 2020 and into 2021 on the Charitls activits'es. While the outbreak is likely to cause some changes to the chariws business, Ihe Charity currently holds a comfortable level of reserves and ts fixed costs are not signtficanl. It has the ability lo align tts adiwties lo the level gf reserves available. The Trustees are optimisliG about the fundraising outlook for the next iwefve months. Page 26 THE HPV AND ANAL CANCER FOUNDATION LIMITED Detailed Statement of Financial Activities for the Year Ended 31 December 2020 2020 2019 INCOME AND ENDOWMENTS Donations and legacies Donations 17,061 11,790 Other trading a¢tivitie$ Fundraising events 73,105 428,398 Investment income Deposit account interesl 20 55 Totsl Sncomlng resources 90.186 440,243 EXPENDITURE Raising donations and legacies Wages Development expenses Marketing Miscellaneous expenses Donor software subscription Event Expenses Media 5.611 1S2 638 9,318 49 1,896 117,494 4,149 1.174 4,226 3,300 14,463 133,544 Charitable activities Wages Development Expenses Marketing Miscellaneous Expense Event Expenses Media Internet and Website Grants lo 1nslilub.ons 15.713 6,642 12,939 806 4,226 13,200 6.545 13,235 640 9,318 49 117,496 16,597 7,963 73,306 152.063 Support costs (Operating) Finan¢e Bank charges 177 422 other Wages Carried fotward 16.082 16,082 35,763 35.763 This page doès not fom part of thè ststutwffinancial statemènts Page 27 THE HPV AND ANAL CANCER FOUNDATION LIMITED Detailed Statement of Financial Activities for the Year Ended 31 December 2020 2020 2019 other Brought forward Pensions Rent and Rates Insurance Fees and subscriptions Telephone, pnnling, FK)stsge and stslionery Sundries Travel and M*tings Consultancy fees Conference expenses 16,082 4,847 8,58T 244 413 404 831 159 5,439 1,196 35,763 4,478 8,192 40 449 870 418 3,512 4,420 193 38.202 58,335 Governance costs Independent Examinerfs fee Accountancy and legal fees 2,640 2,645 481 3,120 3,126 Total resources expended 129,268 347.490 Nat l•xpènditur•lllncomè 139,082) 92,753 This page doès not fom part of thè ststutwffinancial statemènts Page 28